www.fdanews.com/articles/73097-favrille-announces-initiation-of-phase-ii-clinical-trial-in-europe
Favrille Announces Initiation of Phase II Clinical Trial in Europe
June 7, 2005
Favrille has announced that the first patient has been enrolled in a physician-sponsored Phase II clinical trial evaluating the company's lead product candidate, FavId.
The European-only trial is being conducted by Franco Cavalli and is open to patients with all subtypes of indolent B-cell non-Hodgkin's lymphoma.
Both treatment-naive patients and patients who are relapsed or refractory to prior treatments for their disease are eligible for the trial.